Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1366 - METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC)


10 Oct 2016


Poster display


Peter Schmid


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


P. Schmid1, M. Melisko2, D.A. Yardley3, K. Blackwell4, A. Forero5, G. Ouellette6, Y. He7, R.G. Bagley8, J. Zhang8, L.T. Vahdat9

Author affiliations

  • 1 Centre For Experimental Cancer Medicine, Barts Cancer Institute-Queen Mary University of London, EC1M 6BQ - London/GB
  • 2 Department Of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco/US
  • 3 Breast Cancer Research Program, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville/US
  • 4 Department Of Medicine, Duke University Medical Center, Durham/US
  • 5 Department Of Medicine, University of Alabama at Birmingham, Birmingham/US
  • 6 Clinical Operations, Celldex Therapeutics, Inc., Hampton/US
  • 7 Biostatistics, Celldex Therapeutics, Inc., Hampton/US
  • 8 Clinical Science, Celldex Therapeutics, Inc., Hampton/US
  • 9 Breast Cancer Research Program, Weill Cornell Medicine, New York/US


Abstract 1366


Glycoprotein NMB (gpNMB) is an internalizable transmembrane protein overexpressed in ∼20% of breast cancer (BC) including ∼40% of TNBC. gpNMB is a poor prognostic marker in BC (Rose CCR 2010) and implicated in tumor invasion, metastasis, and angiogenesis. GV is a novel ADC delivering the potent cytotoxin MMAE to gpNMB expressing cancer cells. In a Phase 1/2 study and in the Phase 2 EMERGE study, GV was well tolerated and demonstrated promising activity, particularly in TNBC and/or gpNMB overexpressing (≥25% tumor cells; gpNMB+) BC. GV toxicity included rash, neutropenia and neuropathy (primarily grade 1 and 2). In EMERGE subset analyses, objective response rate (ORR) for GV vs. investigator's choice chemotherapy = 30% (7/23) vs. 9% (1/11) in gpNMB+ BC; 18% (5/28) vs. 0% (0/11) in TNBC; and 40% (4/10) vs. 0% (0/6) in gpNMB+ TNBC. Improvements in PFS (hazard ratio (HR) = 0.11; 95% CI, 0.02 to 0.57) and OS (HR = 0.14; 95% CI, 0.03 to 0.59) were also apparent in gpNMB+ TNBC.

Trial design

The METRIC Trial (NCT#01997333) is an ongoing international, 2-arm Phase 2, registrational, TNBC study open in the USA, Canada, Australia, Spain and UK with sites planned in France, Germany and Italy. Pts are randomized 2:1 to GV (1.88 mg/kg IV q3w) or capecitabine (2,500 mg/m2 PO d1-14 q3w) until progression or intolerance. Eligibility Criteria Key eligibility criteria: ≥25% tumor epithelium gpNMB+ by central IHC screening; estrogen and progesterone receptors

Clinical trial identification

NCT #01997333; EudraCT #2015-003693-33

Legal entity responsible for the study

Celldex Therapeutics, Inc.


Celldex Therapeutics, Inc.


G. Ouellette, Y. He, J. Zhang: Full time employee of and stock ownership in Celldex Therapeutics, Inc.

R.G. Bagley: Full time employee of and stock ownership in Celldex Therapeutics, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings